2020 American Transplant Congress
The Safety and Effectiveness and of Isoniazid Empirical Prophylaxis Compared to Screening Based Prophylaxis Post Lung Transplantation
*Purpose: Even though guidelines recommend using isoniazid (INH) for TB prophylaxis depending on donors and recipients’ screening tests, previous studies supported its use in all…2020 American Transplant Congress
Alternate Triazole Therapy for Breakthrough Invasive Fungal Disease in Lung Transplant Recipients on Triazole Prophylaxis
Cleveland Clinic Foundation, Cleveland, OH
*Purpose: Invasive fungal diseases (IFD) are a leading cause of infection related morbidity and mortality in lung transplant (LT) recipients. Data regarding outcomes of breakthrough…2020 American Transplant Congress
Isavuconazole (ISA) versus Voriconazole (VOR) Prophylaxis (px) in Lung Transplant Recipients (LTR)
University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: IFI is a significant complication following lung transplant (LT). VOR was universal antifungal (AF) px in our LT program from 2004-09/2015, at which time…2020 American Transplant Congress
Antimicrobial Prophylaxis Post Antibody Mediated Rejection Treatment in Pediatric Kidney Transplant Recipients: Interim Report from the Paramour “PediAtric Renal AMr Outcomes” Study
*Purpose: Universal guidelines do not exist for post antibody mediated rejection (AMR) treatment antimicrobial prophylaxis (ppx) in pediatric kidney transplant (KT) recipients. We sought to…2019 American Transplant Congress
Experience With Letermovir Use For The Management Of Cytomegalovirus In Solid Organ Transplant Recipients
*Purpose: Letermovir is a new antiviral recently approved for cytomegalovirus (CMV) prophylaxis in CMV-seropositive hematopoietic-cell transplant recipients. Its off-label use in solid organ transplant (SOT)…2019 American Transplant Congress
Incidence of Cytomegalovirus in Moderate Risk Kidney Transplant Recipients Receiving Low Dose Valganciclovir
*Purpose: Studies evaluating the efficacy of valganciclovir (VGC) at 450 mg daily versus 900 mg daily for the prevention of cytomegalovirus (CMV) in kidney transplant…2019 American Transplant Congress
Target Itraconazole Trough Concentration for Prophylaxis in Lung Transplant
*Purpose: Itraconazole (ITR) therapeutic drug monitoring (TDM) for prophylaxis in lung transplant recipients (LTR) is not well characterized. Our purpose was to evaluate ITR trough…2019 American Transplant Congress
Outbreak of Pneumocystis Pneumonia in a Transplant Center Linked to a Single Genotype of Pneumocystis jirovecii: Effects of Cytomegalovirus Infection and Allograft Rejection
*Purpose: Although post-transplant pneumocystis pneumonia (PCP) outbreaks have been reported from Asia, Australia and Europe, there are limited data from North America. We investigated transmissibility…2019 American Transplant Congress
Pneumocystis Prophylaxis in Solid Organ Transplant Recipients at Two Large Transplant Centers from 2015-2016: Why Not Trimethoprim-Sulfamethoxazole?
*Purpose: Trimethoprim-sulfamethoxazole (T/S) is the drug of choice for Pneumocystis jirovecii pneumonia (PJP) prophylaxis (ppx) after solid organ transplant (SOT). Perceived side effects may lead…2019 American Transplant Congress
Impact of a Short Duration, Narrow Spectrum Perioperative Antibiotic Prophylaxis Regimen on Multi-Drug Resistant Surgical Site Infections in Adult Orthotopic Liver Transplantation
*Purpose: There is a paucity of data defining the optimal agent and timing of peri-operative antimicrobial prophylaxis in orthotopic liver transplantation (OLT). The purpose of…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 14
- Next Page »